ClinicalTrials.gg
CompletedNCT06695442COVIDOMICSUpdated Nov 19, 2024

Predictive Model for High-Flow Nasal Cannula Failure in COVID-19-related Acute Hypoxemic Respiratory Failure Based on Metabolomics and Clinical Data

An observational study in Acute Hypoxemic Respiratory Failure and COVID 19, sponsored by Hospital del Mar Research Institute (IMIM). Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Hospital del Mar Research Institute (IMIM) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
111
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Respiratory Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Respiratory Insufficiency · Spain.

Enrollment
26th of 31
111 · median 298
Started
2020
with 10 others
Observational
31 of 69
5 open now
Registered
55th of 69
by date
Lead sponsor
3 of 69
Hospital del Mar Research Institute (IMIM)

Among the 69 studies in Respiratory Insufficiency with a site in Spain, this one is the 26th largest by enrollment of the 31 observational ones that give a count, is one of 11 that started in 2020, is one of 31 observational ones, and was the 55th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

11 of the 69 studies in Respiratory Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Respiratory Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

The aim of this prospective observational cohort study is to develop a predictive model for high-flow nasal cannula (HFNC) failure in patients with acute hypoxemic respiratory failure (AHRF) caused by SARS-CoV-2. By combining clinical data and metabolomic profiles, the study seeks to answer:

  • Can integrating clinical parameters with metabolomic markers enhance the prediction of HFNC failure in AHRF patients?

Participants with AHRF due to SARS-CoV-2 receiving HFNC under standard-of-care protocols will be monitored until hospital discharge or death. Blood samples for metabolomic analysis will be collected at inclusion.

Read the detailed description

This prospective observational cohort study focuses on developing and validating a predictive model for HFNC failure in patients with SARS-CoV-2-related AHRF, combining clinical parameters and metabolomic profiling. Patients received standard-of-care therapy based on hospital protocols, with clinical data and plasma samples collected at inclusion (T0) for laboratory and metabolomic analyses.

The study consists of two cohorts: a Training Cohort (March 2020 to April 2021) for model development and a Validation Cohort (May 2021 to October 2021) for model validation and external testing. HFNC outcomes were classified as success or failure, with failure defined as requiring orotracheal intubation (OTI). Advanced machine-learning techniques were employed for feature selection and model optimization, targeting precise integration of clinical and metabolomic data.

This model seeks to enhance early identification of HFNC failure risk, enabling timely interventions and personalized management in critically ill AHRF patients.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure
  • COVID 19

Keywords

  • Acute Hypoxemic Respiratory Failure
  • COVID-19
  • High-Flow Nasal Cannula
  • Predictive Model
  • Machine Learning
  • Metabolomics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to Hospital del Mar in Barcelona, Spain

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years old) with acute hypoxemic respiratory failure (AHRF) confirmed as secondary to SARS-CoV-2 infection via PCR testing.
  • Requirement for high-flow nasal cannula (HFNC) initiated within 48 hours of hospital admission.

Exclusion criteria

Exclusion Criteria:

  • Patients under the age of 18
  • Patients with active "do not resuscitate" (DNR) orders at the time of inclusion.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
111 participants (actual)
Target follow-up
1 Month
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Training Cohort

    Participants included from March 2020 to April 2021 for model development.

  • Validation Cohort

    Participants included from May 2021 to October 2021 for model validation.

06

What researchers measure

Primary outcomes

  1. Predictive Model Development

    Area Under the Receiver Operating Characteristic Curve (AUC) of the final predictive model for identifying HFNC failure, measured at the time of study inclusion (T0).

    Time frame: From the initiation of HFNC until the need for intubation, hospital discharge, or death, whichever occurs first (up to 28 days). Completed using the Training Cohort (March 2020 to April 2021).

Secondary outcomes

  1. Identification of Key Metabolites

    Concentrations of key metabolomic markers (e.g., anthranilic acid, octanoic acid) associated with HFNC failure, measured at T0.

    Time frame: At study inclusion (T0).

  2. Validation of the Predictive Model

    Performance of the predictive model in the Validation Cohort. Area Under the Receiver Operating Characteristic Curve (AUC) of the final predictive model for identifying HFNC failure, measured at the time of study inclusion (T0).

    Time frame: From the initiation of HFNC until the need for intubation, hospital discharge, or death, whichever occurs first (up to 28 days). Completed during the Validation Cohort phase (May to October 2021).

07

Study locations

1 site
  • Hospital del Mar
    Barcelona, 08003, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Sep 2021, 18 months.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 18 months is below that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 19, 2024
StartActual
Mar 1, 2020
Primary completionActual
Sep 30, 2021
CompletionActual
Dec 1, 2021
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06695442
Lead sponsor
Hospital del Mar Research Institute (IMIM)
Collaborators
Fundacio La Marató de TV3, Instituto de Salud Carlos III, European Union
Responsible party
Andrea Castellvi (Clinical Investigator, Hospital del Mar) — Principal investigator
First posted
Nov 19, 2024
Start date
Mar 1, 2020
Primary completion
Sep 30, 2021
Completion
Dec 1, 2021
Last update
Nov 19, 2024

Study contacts

Óscar J Pozo, PhD
principal investigator · Hospital del Mar Research Institute
Joan Ramon Masclans Enviz, MD, PhD
principal investigator · Hospital del Mar

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion